More detail and an honest question. There was a lot to like in the conference call, such as management's openness to talk details. Though some might not like all the answers, I appreciated CEO Hutchins' willingness to be specific. Ex: Dr. Messing's report will not be publicly published (tips our hand), not promoting the 15 minute process advantage (complicates FDA review), management tried to keep expenses under control last quarter, legal fees to prep for FDA are a lot and are $ 180,000 in accounts payable already, we have firm ownership of our patents, units proposed for market ready configuration will be ready for FDA mandated human tests by the end of September, we do not know yet if the FDA will require a lot of human tests-fewer human tests- or no human tests, we do not yet know precisely what these tests will cost or how long they will take, we DO know that we will have to raise more money before FDA mandated testing, once approved by FDA we could be filling the first orders relatively quickly, the potential per unit profit margin is on the high side of the medical device range, the CEO has not purchased any shares this past year and has no stated plans to buy any, stock price promotion will take the form of marketing to doctors and finance industry players in the near term and not to the independent investor community, the company is for sale if a good match can be made and our management has a very positive view of Stryker (one of our potential buyers). And here is my question: why is it going to take until the end of September to have FDA test ready units (given that we have been working on miniaturizing and perfecting a working model for a year)? My impression is that we can go into any required human testing as soon as the units are ready. So we need to expidite this. It appears the next promotable news event will be when we have units ready and the FDA indicates what degree of testing they will require. So I am seeing that as our next stock inflection point, and that could be eight months away. So until then management will try to increase stock value by promoting the current pitch package to industry insiders. Note how demand has soared since that same presentation package was pitched at Noblecon. And sometime near the end of September we will have to raise more money. I am in for the long haul and I am holding my shares, but investors may need to understand that there may not be a catalyst for share value growth for some months. Those wishing to add shares may have quite a while yet to value shop. But there appears to be an increasing likelihood that the patient investor will be well rewarded. Dilution may be on the menu before then though, but a buyout could occur at any time as well.
